MTOR and graft versus host disease: Given the previously mentioned pitfalls of CN and mTOR inhibitor-containing GvHD prevention regimens, our work over the last several years focused on exploiting PTCy in order develop CN and mTOR inhibitor-free GvHD preventive combinations.